FDA Logo After consenting a drug to prevent HIV infection, the US Food and Drug Administration (FDA) has now approved of a new weight management drug called Qsymia. This medication is to be taken along with low-calorie consumption and exercise for chronic weight control.

The medicine is approved for use in obese adults with BMI of 30 or more as well as overweight persons with BMI 27 or higher. Those suffering from any 1 weight-related health issue such as diabetes, high cholesterol, or hypertension are eligible to take this drug. It should not be taken during pregnancy, the team warned. According to the panel, this medication is not supposed to be consumed by hyperthyroidism or glaucoma patients.

“Obesity threatens the overall well being of patients and is a major public health concern. Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition,” remarked Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

In the trial that was conducted, obese and overweight persons were instructed to exercise and consume low calorie food. After one year of treatment with the medication in suggested and high levels, subjects experienced roughly 6.7% and 8.9% of weight loss, correspondingly. The doses of the drug can be altered as per the responses shown by the concerned persons.

Some of the side effects reported included tingling sensations in the feet and hands, different taste perceptions, constipation, insomnia, dry mouth and dizziness. Qsymia is sold by Vivus.